124Iodine Evuzamitide Positron Emission Tomography in Patients with Established or Suspected Cardiac Amyloidosis

“These 124 evuzamitide data demonstrate the potential of a single test to help health care providers identify or exclude cardiac amyloidosis. Clinically, a sensitive, specific and quantitative PET tracer could help distinguish cardiac amyloidosis from other causes of heart failure, differentiate amyloid subtypes when used alongside appropriate laboratory testing, and track changes in cardiac amyloid burden over time.”

“We are very excited about the positive topline results of the REVEAL study and are looking forward to sharing the data with the scientific community.”